
    
      This is an open-label study being conducted at 18 centers. The dose of 10 mg was chosen for
      daily continuous use of ulipristal acetate (UPA). The study will enroll approximately 300
      subjects to use the UPA for 6 months (182 days). In addition to contraceptive efficacy,
      safety, overall acceptability of the product, and the number of bleeding/spotting days will
      be assessed.
    
  